Sun Pharma and Takeda Ink Pact To Market Gastrointestinal Drug

Sun Pharmaceutical Industries Limited stated that it has signed a non-exclusive patent licensing deal with Takeda Pharmaceutical Company Limited (Takeda) to market vonoprazan tablets 10 mg and 20 mg in India under the brand name "Voltapraz". Vonoprazan is a new, orally active potassium competitive acid blocker (PCAB) that is utilized for the treatment of reflux esophagitis and other acid peptic illnesses.

Nidlegy is administered intralesionally for four weeks and works by strengthening the immune system against neoplastic tumors. Under the terms of this agreement, the pharmaceutical company gave Sun Pharma non-exclusive patent licensing rights for the marketing of vonoprazan in India.

Commenting on the development, Kirti Ganorkar, CEO - India business, Sun Pharma said, “Sun Pharma is a leader in gastroenterology and we are excited to introduce vonoprazan in India under non-exclusive patent license from Takeda. This partnership demonstrates our commitment to gastrointestinal health by providing patients and healthcare practitioners with a novel treatment option to manage reflux esophagitis and other acid peptic disorders.” Gastroesophageal reflux disease (GERD) is ubiquitous throughout India, regardless of geography or rural/urban location. The prevalence of GERD in the Indian population ranges between 5% and 28.5%. Age, body mass index (BMI), non-vegetarian diet, tea/coffee intake, tobacco use, and alcohol usage are all risk factors for GERD.

The US FDA approved vonoprazan in November 2023 for the treatment and maintenance of healing of all grades of erosive esophagitis, as well as relief of heartburn associated with erosive esophagitis, in combination with amoxicillin and clarithromycin or amoxicillin alone for the treatment of Helicobacter pylori (H. pylori) infection in adults.